Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.

Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA.

Ann Clin Biochem. 1998 Jan;35 ( Pt 1):99-103.

PMID:
9463746
2.

Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.

Ng WW, Tong KJ, Tam TN, Lee SD.

Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jun;55(6):438-46.

PMID:
7634181
3.

Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues.

Kitagawa Y, Iwai M, Muramatsu A, Tanaka S, Mori T, Harada Y, Okanoue T, Kashima K.

Histopathology. 2002 May;40(5):472-9.

PMID:
12010368
4.

Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.

Pezzilli R, Calculli L, Melzi d'Eril G, Barassi A.

Hepatobiliary Pancreat Dis Int. 2016 Oct;15(5):553-557.

PMID:
27733327
5.

Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.

Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR.

World J Gastroenterol. 2004 Feb 1;10(3):427-32.

6.

A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.

Kumar Y, Pinedo IR, Tapuria N, Zabron A, Davidson BR.

Eur J Gastroenterol Hepatol. 2008 Oct;20(10):1006-11. doi: 10.1097/MEG.0b013e3282f857a7.

PMID:
18787469
7.

Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.

Ince AT, Yıldız K, Baysal B, Danalıoğlu A, Kocaman O, Tozlu M, Gangarapu V, Sarbay Kemik A, Uysal Ö, Şentürk H.

Turk J Gastroenterol. 2014 Apr;25(2):162-9. doi: 10.5152/tjg.2014.6056.

8.

Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?

Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.

Turk J Gastroenterol. 2003 Sep;14(3):181-4. Erratum in: Turk J Gastroenterol. 2004 Jun;15(2):122. Saydam, Gül [correction of Ersavaşti,Gül].

9.

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.

Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.

Eur J Surg Oncol. 2005 Mar;31(2):164-9.

PMID:
15698733
10.

[Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].

Grotowski M, Maruszyński M, Piechota W.

Pol Merkur Lekarski. 2001 Dec;11(66):476-9. Polish.

PMID:
11899841
11.

The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.

Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H; Tumor Marker Committee.

Gastric Cancer. 2003;6(3):142-5.

PMID:
14520526
12.

Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis.

Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R.

Int J Biol Markers. 2000 Jul-Sep;15(3):226-30.

PMID:
11012098
13.

Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.

Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T.

J Clin Gastroenterol. 2001 Jan;32(1):41-4.

PMID:
11154168
14.

Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population.

Zhang D, Yu M, Xu T, Xiong B.

Hepatogastroenterology. 2013 Sep;60(126):1297-301. doi: 10.5754/hge121125.

PMID:
23933921
15.

Primary thymic adenocarcinoma with production of carbohydrate antigen 19-9 and carcinoembryonic antigen.

Misao T, Yamamoto Y, Nakano H, Toyooka S, Yamane M, Satoh K.

Jpn J Thorac Cardiovasc Surg. 2004 Jan;52(1):30-2.

PMID:
14760989
16.

Are elevated levels of the tumour marker CA19-9 of any clinical significance?--an evaluation.

McLaughlin R, O'Hanlon D, Kerin M, Kenny P, Grimes H, Given HF.

Ir J Med Sci. 1999 Apr-Jun;168(2):124-6.

PMID:
10422394
17.

Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.

Bjerner J, Høgetveit A, Wold Akselberg K, Vangsnes K, Paus E, Bjøro T, Børmer OP, Nustad K.

Scand J Clin Lab Invest. 2008;68(8):703-13. doi: 10.1080/00365510802126836.

PMID:
18609108
18.

[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].

Li YH, An X, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH.

Ai Zheng. 2009 Sep;28(9):939-44. Chinese.

PMID:
19728911
19.

A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.

Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP.

Br J Cancer. 2011 Oct 25;105(9):1370-8. doi: 10.1038/bjc.2011.376. Epub 2011 Oct 4.

20.

The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.

Tocchi A, Costa G, Lepre L, Liotta G, Mazzoni G, Cianetti A, Vannini P.

J Cancer Res Clin Oncol. 1998;124(8):450-5.

PMID:
9750022

Supplemental Content

Support Center